Tags

Type your tag names separated by a space and hit enter

SDF-1α as a therapeutic stem cell homing factor in myocardial infarction.
Pharmacol Ther. 2011 Jan; 129(1):97-108.P&T

Abstract

Myocardial infarction is associated with persistent muscle damage, scar formation and depressed cardiac performance. Recent studies have demonstrated the clinical significance of stem cell-based therapies after myocardial infarction with the aim to improve cardiac remodeling and function by inducing the reconstitution of functional myocardium and formation of new blood vessels. Stem cell homing signals play an important role in stem cell mobilization from the bone marrow to the ischemic cardiac environment and are therefore crucial for myocardial repair. To date, the most prominent stem cell homing factor is the chemokine SDF-1α/CXCL12. This protein was shown to be significantly upregulated in many experimental models of myocardial infarction and in patients suffering from ischemic cardiac diseases, suggesting the involvement in the pathophysiology of these disorders. A number of studies focused on manipulating SDF-1α and its receptor CXCR4 as central regulators of the stem cell mobilization process. Targeted expression of SDF-1α after myocardial infarction was shown to result in increased engraftment of bone marrow-derived stem cells into infarcted myocardium. This was accompanied by beneficial effects on cardiomyocyte survival, neovascularization and cardiac function. Thus, the SDF-1/CXCR4 axis seems to be a promising novel therapeutic approach to improve post-infarction therapy by attracting circulating stem cells to remain, survive and possibly differentiate in the infarct area. This review will summarize clinical trials of stem cell therapy in patients with myocardial infarction. We further discuss the basic findings about SDF-1α in stem cell recruitment and its therapeutic implications in experimental myocardial infarction.

Authors+Show Affiliations

Department of Cardiovascular and Metabolic Disease Research, Max Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Str. 10, D-13125 Berlin, Germany.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

20965212

Citation

Ghadge, Santhosh K., et al. "SDF-1α as a Therapeutic Stem Cell Homing Factor in Myocardial Infarction." Pharmacology & Therapeutics, vol. 129, no. 1, 2011, pp. 97-108.
Ghadge SK, Mühlstedt S, Ozcelik C, et al. SDF-1α as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol Ther. 2011;129(1):97-108.
Ghadge, S. K., Mühlstedt, S., Ozcelik, C., & Bader, M. (2011). SDF-1α as a therapeutic stem cell homing factor in myocardial infarction. Pharmacology & Therapeutics, 129(1), 97-108. https://doi.org/10.1016/j.pharmthera.2010.09.011
Ghadge SK, et al. SDF-1α as a Therapeutic Stem Cell Homing Factor in Myocardial Infarction. Pharmacol Ther. 2011;129(1):97-108. PubMed PMID: 20965212.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SDF-1α as a therapeutic stem cell homing factor in myocardial infarction. AU - Ghadge,Santhosh K, AU - Mühlstedt,Silke, AU - Ozcelik,Cemil, AU - Bader,Michael, Y1 - 2010/10/20/ PY - 2010/09/28/received PY - 2010/09/30/accepted PY - 2010/10/23/entrez PY - 2010/10/23/pubmed PY - 2011/3/31/medline SP - 97 EP - 108 JF - Pharmacology & therapeutics JO - Pharmacol Ther VL - 129 IS - 1 N2 - Myocardial infarction is associated with persistent muscle damage, scar formation and depressed cardiac performance. Recent studies have demonstrated the clinical significance of stem cell-based therapies after myocardial infarction with the aim to improve cardiac remodeling and function by inducing the reconstitution of functional myocardium and formation of new blood vessels. Stem cell homing signals play an important role in stem cell mobilization from the bone marrow to the ischemic cardiac environment and are therefore crucial for myocardial repair. To date, the most prominent stem cell homing factor is the chemokine SDF-1α/CXCL12. This protein was shown to be significantly upregulated in many experimental models of myocardial infarction and in patients suffering from ischemic cardiac diseases, suggesting the involvement in the pathophysiology of these disorders. A number of studies focused on manipulating SDF-1α and its receptor CXCR4 as central regulators of the stem cell mobilization process. Targeted expression of SDF-1α after myocardial infarction was shown to result in increased engraftment of bone marrow-derived stem cells into infarcted myocardium. This was accompanied by beneficial effects on cardiomyocyte survival, neovascularization and cardiac function. Thus, the SDF-1/CXCR4 axis seems to be a promising novel therapeutic approach to improve post-infarction therapy by attracting circulating stem cells to remain, survive and possibly differentiate in the infarct area. This review will summarize clinical trials of stem cell therapy in patients with myocardial infarction. We further discuss the basic findings about SDF-1α in stem cell recruitment and its therapeutic implications in experimental myocardial infarction. SN - 1879-016X UR - https://www.unboundmedicine.com/medline/citation/20965212/SDF_1α_as_a_therapeutic_stem_cell_homing_factor_in_myocardial_infarction_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0163-7258(10)00210-X DB - PRIME DP - Unbound Medicine ER -